Form 4: Guardant Health Director Reports Future RSU Vesting Event

Guardant Health, Inc. Director Steve E. Krognes has filed a Form 4 detailing the future vesting of 154 common shares from Restricted Stock Units on June 30, 2025.

Summary

• Steve E. Krognes, a Director at Guardant Health, Inc. (GH), reported a transaction involving the vesting of Restricted Stock Units (RSUs).
• On June 30, 2025, 154 shares of common stock will vest from an RSU award.
• This RSU award was originally granted on August 9, 2022.
• The award's vesting schedule began with 25% vesting on June 30, 2023, with the remaining 75% vesting in substantially equal installments on each monthly anniversary of June 30, 2023, over a three-year period.
• Following this transaction, Krognes will beneficially own 17,819 shares of common stock directly and 1,852 Restricted Stock Units directly.
• The transaction is reported as an exercise or conversion of a derivative security with a price of $0, typical for RSU vesting.

Sentiment

Score: 6

Explanation: The filing reports a routine, pre-planned vesting of equity compensation for a director. While not directly indicative of operational performance, it reflects ongoing executive alignment and compensation structure, which is generally a neutral to slightly positive signal regarding corporate governance and incentive alignment.

Positives

• Indicates continued alignment of a director's interests with shareholders through equity compensation.
• The vesting is part of a pre-planned compensation structure, suggesting stability in executive incentives.

Future Outlook

The filing indicates a pre-planned future vesting event for a director's equity compensation, part of a multi-year vesting schedule for Restricted Stock Units granted in 2022.

Industry Context

This filing is a routine disclosure of insider equity compensation, common across all industries for publicly traded companies, reflecting standard practices for aligning executive incentives with company performance over time.

Comparison to Industry Standards

• The vesting of Restricted Stock Units at a $0 exercise price is a standard form of equity compensation for directors and executives in the biotechnology and healthcare sectors.
• This aligns with common practices seen in companies like Illumina (ILMN) or Exact Sciences (EXAS) where long-term incentives are tied to share performance and continued service.

Stakeholder Impact

• Shareholders: The vesting of shares increases the outstanding share count slightly over time, but it is a standard part of director compensation and aligns the director's interests with shareholder value.
• Management: Reinforces the compensation structure for the director, aligning their long-term interests with the company's performance.

Next Steps

• Continued monthly vesting of the remaining 1,852 Restricted Stock Units over the three-year period from June 30, 2023.

Key Dates

Keywords

Guardant Health, GH, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Director Compensation, Equity Compensation, Steve Krognes